ACE inhibitors or angiotensin-converting enzyme inhibitors, are a group of pharmaceuticals that are used primarily in treatment of hypertension and congestive heart failure, in some cases as the drugs of first choice.
- 1 Clinical use
- 2 The renin-angiotensin-aldosterone system (RAAS)
- 3 Effects
- 4 Adverse effects
- 5 Examples
- 6 Comparative information
- 7 Blood Brain Barrier Crossing ACE Inhibitors & Dementia, Blood Pressure, RAAS
- 8 Contraindications and precautions
- 9 Angiotensin II receptor antagonists
- 10 History
- 11 See also
- 12 References
ACE inhibitors are used primarily in the treatment of hypertension,though they are also sometimes used in those with cardiac failure,renal disease,or systemic sclerosis
The renin-angiotensin-aldosterone system (RAAS)
This system is activated in response to hypotension, decreased sodium concentration in the distal tubule, decreased blood volume and renal sympathetic nerve stimulation. In such a situation, the kidneys release renin which cleaves the liver-derived angiotensinogen into angiotensin I. Angiotensin I is then converted to angiotensin II via the ACE in the pulmonary circulation as well as in the endothelium of blood vessels in many parts of the body. The system in general aims to increase blood pressure. This homeostatic mechanism: a drop in blood pressure causing the kidney to release a substance that increases it again, may be of very ancient evolutionary origin. The increase ensures the kidney itself is kept perfused, a precondition for human life.
ACE inhibitors prevent the angiotensin converting enzyme (ACE) from producing angiotensin II. This causes a central enhancement of parasympathetic activity in healthy volunteers and patients with heart failure. This action may reduce the prevalence of malignant cardiac arrhythmias, and the reduction in sudden death reported in large clinical trials.
The ACE inhibitor enalapril has also been shown to reduce cardiac cachexia in patients with chronic heart failure. Cachexia is a poor prognostic sign in patients with chronic heart failure. ACE-inhibitors are now used to reverse frailty and muscle wasting in elderly patients without heart failure.
ACE inhibitors block the conversion of angiotensin I to angiotensin II. They therefore lower arteriolar resistance and increase venous capacity; increase cardiac output and cardiac index, stroke work and volume, lower renovascular resistance, and lead to increased natriuresis (excretion of sodium in the urine).
Normally, angiotensin II will have the following effects:
- vasoconstriction (narrowing of blood vessels), which may lead to increased blood pressure and hypertension
- – constriction of the efferent arterioles of the kidney, leading to increased perfusion pressure in the glomeruli.
- ventricular remodeling of the heart, which may lead to ventricular hypertrophy and CHF
- stimulation of the adrenal cortex to release aldosterone, a hormone that acts on kidney tubules to retain sodium and chloride ions and excrete potassium. Sodium is a "water-holding" molecule, so water is also retained, which leads to increased blood volume, hence an increase in blood pressure.
- stimulation of the posterior pituitary to release vasopressin (also known as anti-diuretic hormone (ADH)) which also acts on the kidneys to increase water retention.
- decrease renal protein kinase C
With ACE inhibitor use, the effects of angiotensin II are prevented, leading to decreased blood pressure.
Epidemiological and clinical studies have shown that ACE inhibitors reduce the progress of diabetic nephropathy independently from their blood pressure-lowering effect. This action of ACE inhibitors is utilised in the prevention of diabetic renal failure.
ACE inhibitors have been shown to be effective for indications other than hypertension even in patients with normal blood pressure. The use of a maximum dose of ACE inhibitors in such patients (including for prevention of diabetic nephropathy, congestive heart failure, prophylaxis of cardiovascular events) is justified because it improves clinical outcomes, independent of the blood pressure lowering effect of ACE inhibitors. Such therapy, of course, requires careful and gradual titration of the dose to prevent the effects of rapidly decreasing blood pressure (dizziness, fainting, etc.).
Common adverse drug reactions include: hypotension, cough, hyperkalemia, headache, dizziness, fatigue, nausea and renal impairment. There is also some evidence to suggest that ACE inhibitors might increase inflammation-related pain.
A persistent dry cough is a relatively common adverse effect believed to be associated with the increases in bradykinin levels produced by ACE inhibitors, although the role of bradykinin in producing these symptoms remains disputed by some authors. Patients who experience this cough are often switched to angiotensin II receptor antagonists.
Rash and taste disturbances, infrequent with most ACE inhibitors, are more prevalent in captopril and is attributed to its sulfhydryl moiety. This has led to decreased use of captopril in clinical setting, although it is still used in scintigraphy of the kidney.
Renal impairment is a significant adverse effect of all ACE inhibitors. The reason for this is still unknown. Some suggest that it is associated with their effect on angiotensin II-mediated homeostatic functions such as renal blood flow. Renal blood flow may be affected by angiotensin II because it vasoconstricts the efferent arterioles of the glomeruli of the kidney, thereby increasing glomerular filtration rate (GFR). Hence, by reducing angiotensin II levels, ACE inhibitors may reduce GFR, a marker of renal function. Specifically, ACE inhibitors can induce or exacerbate renal impairment in patients with renal artery stenosis. This is especially a problem if the patient is also concomitantly taking an NSAID and a diuretic. When the three drugs are taken together, there is a very high risk of developing renal failure.
ACE inhibitors may cause hyperkalemia. Suppression of angiotensin II leads to a decrease in aldosterone levels. Since aldosterone is responsible for increasing the excretion of potassium, ACE inhibitors ultimately cause retention of potassium.
A severe allergic reaction can occur that rarely can affect the bowel wall and secondarily cause abdominal pain. This "anaphylactic" reaction is very rare as well.
Some patients develop angioedema due to increased bradykinin levels. There appears to be a genetic predisposition towards this adverse effect in patients who degrade bradykinin more slowly than average.
In pregnant women, ACE inhibitors taken during the first trimester have been reported to cause major congenital malformations, stillbirths, and neonatal deaths. Commonly reported fetal abnormalities include hypotension, renal dysplasia, anuria/oliguria, oligohydramnios, intrauterine growth retardation, pulmonary hypoplasia, patent ductus arteriosus, and incomplete ossification of the skull.
ACE inhibitors can be divided into three groups based on their molecular structure:
- Captopril (trade name Capoten), the first ACE inhibitor
This is the largest group, including:
- Enalapril (Vasotec/Renitec)
- Ramipril (Altace/Tritace/Ramace/Ramiwin)
- Quinapril (Accupril)
- Perindopril (Coversyl/Aceon)
- Lisinopril (Lisodur/Lopril/Novatec/Prinivil/Zestril)
- Benazepril (Lotensin)
- Fosinopril (Monopril) is the only member of this group
- Casokinins and lactokinins are breakdown products of casein and whey that occur naturally after ingestion of milk products, especially cultured milk. Their role in blood pressure control is uncertain.
- The Lactotripeptides Val-Pro-Pro and Ile-Pro-Pro produced by the probiotic Lactobacillus helveticus or derived from casein have been shown to have ACE-inhibiting and antihypertensive functions.
Comparatively, all ACE inhibitors have similar antihypertensive efficacy when equivalent doses are administered. The main point-of-difference lies with captopril, the first ACE inhibitor, which has a shorter duration of action and increased incidence of certain adverse effects.
Certain agents in the ACE inhibitor class have been proven, in large clinical studies, to reduce mortality post-myocardial infarction, prevent development of heart failure, etc. The ACE inhibitor most prominently recognized for these qualities is ramipril (Altace). Because ramipril has been shown to reduce mortality rates even among patient groups not suffering from hypertension, there are some (mostly drug reps) who believe that ramipril's benefits may extend beyond those of the general abilities it holds in common with other members of the ACE inhibitor class.
The ACE inhibitors have different strengths with different starting dosages. Dosage should be adjusted according to the clinical response.   
|ACE inhibitors dosages for hypertension|
|Note: bid = 2 times a day, tid = 3 times a day, d = daily
Drug dosages from Drug Lookup, Epocrates Online.
|Name||Equivalent daily dose||Start||Usual||Maximum|
|Benazepril||10 mg||10 mg||20–40 mg||80 mg|
|Captopril||50 mg (25 mg bid)||12.5–25 mg bid-tid||25–50 mg bid-tid||450 mg/d|
|Enalapril||5 mg||5 mg||10–40 mg||40 mg|
|Fosinopril||10 mg||10 mg||20–40 mg||80 mg|
|Lisinopril||10 mg||10 mg||10–40 mg||80 mg|
|Moexipril||7.5 mg||7.5 mg||7.5–30 mg||30 mg|
|Perindopril||4 mg||4 mg||4–8 mg||16 mg|
|Quinapril||10 mg||10 mg||20–80 mg||80 mg|
|Ramipril||2.5 mg||2.5 mg||2.5–20 mg||20 mg|
|Trandolapril||2 mg||1 mg||2–4 mg||8 mg|
|Name||Equivalent daily dose||Start||Usual||Maximum|
|Note: bid = 2 times a day, tid = 3 times a day, d = daily
Drug dosages from Drug Lookup, Epocrates Online.
|ACE inhibitors dosages for hypertension|
Blood Brain Barrier Crossing ACE Inhibitors & Dementia, Blood Pressure, RAAS
|This section requires expansion.|
Contraindications and precautions
The ACE inhibitors are contraindicated in patients with:
- Previous angioedema associated with ACE inhibitor therapy
- Renal artery stenosis (bilateral, or unilateral with a solitary functioning kidney)
- Hypersensitivity to ACE inhibitors
ACE inhibitors should be used with caution in patients with:
- Impaired renal function
- Aortic valve stenosis or cardiac outflow obstruction
- Hypovolemia or dehydration
- Hemodialysis with high flux polyacrylonitrile membranes
ACE inhibitors are ADEC Pregnancy category D, and should be avoided in women who are likely to become pregnant. In the U.S., ACE inhibitors are required to be labelled with a "black box" warning concerning the risk of birth defects when taking during the second and third trimester. It has also been found that use of ACE inhibitors in the first trimester is also associated with a risk of major congenital malformations, particularly affecting the cardiovascular and central nervous systems.
Potassium supplementation should be used with caution and under medical supervision owing to the hyperkalemic effect of ACE inhibitors.
Angiotensin II receptor antagonists
ACE inhibitors share many common characteristics with another class of cardiovascular drugs called angiotensin II receptor antagonists, which are often used when patients are intolerant of the adverse effects produced by ACE inhibitors. ACE inhibitors do not completely prevent the formation of angiotensin II, as there are other conversion pathways, and so angiotensin II receptor antagonists may be useful because they act to prevent the action of angiotensin II at the AT1 receptor, leaving AT2 receptor unblocked; the latter may have consequences needing further study.
Use in combination
The combination therapy of angiotensin II receptor antagonists with ACE inhibitors may be superior to either agent alone. This combination may increase levels of bradykinin while blocking the generation of angiotensin II and its activity at the AT1 receptor. This 'dual blockade' may be more effective than using an ACE inhibitor alone, because angiotensin II can be generated via non-ACE-dependent pathways. Preliminary studies suggest that this combination of pharmacologic agents may be advantageous in the treatment of essential hypertension, chronic heart failure, and nephropathy. However, more studies are needed to confirm these highly preliminary results. While statistically significant results have been obtained for its role in treating hypertension, clinical significance may be lacking.
Patients with heart failure may benefit from the combination in terms of reducing morbidity and ventricular remodeling.
The most compelling evidence has been found for the treatment of nephropathy: this combination therapy partially reversed the proteinuria and also exhibited a renoprotective effect in patients afflicted with diabetic nephropathy, and pediatric IgA nephropathy.
The first step in the development of (ACE) inhibitors was the discovery of angiotensin converting enzyme (ACE) in plasma by Leonard T. Skeggs and his colleagues in 1956. Brazilian scientist Sergio Ferreira reported in 1965 of a 'bradykinin potentiating factor (BPFs) present in the venom of bothrops jararaca, a South American pit viper.( Brit J Pharmacol & Chemother 1965). Dr SH Ferreira then proceeded to John Vanes laboratory as a Post-Doc with his already isolated BPFs. The conversion of the inactive angiotensin I to the potent angiotensin II was thought to take place in the plasma. However, in 1967, Kevin K. F. Ng and John R. Vane showed that the plasma (ACE) was too slow to account for the conversion of angiotensin I to angiotensin II in vivo. Subsequent investigation showed that rapid conversion occurs during its passage through the pulmonary circulation.
Bradykinin is rapidly inactivated in the circulating blood and it disappears completely in a single passage through the pulmonary circulation. Angiotensin I also disappears in the pulmonary circulation due to its conversion to angiotensin II. Furthermore, angiotensin II passes through the lungs without any loss. The inactivation of bradykinin and the conversion of angiotensin I to angiotensin II in the lungs was thought to be caused by the same enzyme. In 1970, Ng and Vane using bradykinin potentiating factor (BPF) provided by Sérgio Henrique Ferreira showed that the conversion of angiotensin I to angiotensin II was inhibited during its passage through the pulmonary circulation.
Bradykinin potentiating factor (BPF) is derived from the venom of the pit viper (Bothrops jararaca). It is a family of peptides and its potentiating action is linked to inhibition of bradykinin by ACE. Molecular analysis of BPF yielded a nonapeptide BPF teprotide (SQ 20,881) which showed the greatest (ACE) inhibition potency and hypotensive effect in vivo. Teprotide had limited clinical value, due to its peptide nature and lack of activity when given orally. In the early 1970s, knowledge of the structure-activity relationship required for inhibition of ACE was growing. David Cushman, Miguel Ondetti and colleagues used peptide analogues to study the structure of ACE, using carboxypeptidase A as a model. Their discoveries led to the development of captopril, the first orally-active ACE inhibitor in 1975.
Captopril was approved by the United States Food and Drug Administration in 1981. The first non-sulfhydryl-containing (ACE) inhibitor enalapril was marketed two years later. Since then, at least twelve other ACE inhibitors have been marketed.
In 1991, Japanese scientists created the first ever milk-based ACE inhibitor in the form of a fermented milk drink, using specific cultures to liberate the IPP from the dairy protein. Interestingly, Val-Pro-Pro is also liberated in this process—another milk tripeptide with a very similar chemical structure to IPP. Together, these peptides are now often referred to as lactotripeptides. Shortly after this, in 1996, the first human study confirmed the blood pressure lowering effect of IPP in fermented milk. Although twice the amount of VPP is needed to achieve the same ACE inhibiting activity as the originally discovered IPP, it is assumed that VPP also adds to the total blood pressure lowering effect. Since the first lactotripeptides discovery, more than 20 human clinical trials have been conducted in many different countries.
- Angiotensin II receptor antagonist
- Angiotensin Receptor Blockers: Drug discovery and development
- ^ Human Physiology, Silverthorn (Pearson Benjamin Cummings 2004)[page needed]
- ^ Ajayi, Adesuyi A. (1985). "Acute and Chronic Effects of the Converting Enzyme Inhibitors Enalapril and Lisinopril on Reflex Control of Heart Rate in Normotensive Man". Journal of Hypertension 3 (1): 47. doi:10.1097/00004872-198502000-00008. PMID 2987341.
- ^ Adigun, AQ; Asiyanbola B, Ajayi AA (2001). "Cardiac autonomic function in Blacks with congestive heart failure: vagomimetic action, alteration in sympathovagal balance, and the effect of ACE inhibition on central and peripheral vagal tone". Cell Mol Biol 47 (6): 1063–7. PMID 11785658. [verification needed]
- ^ Adigun, A (2001). "The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia". European Journal of Heart Failure 3 (3): 359. doi:10.1016/S1388-9842(00)00146-X. PMID 11378008.
- ^ Anker, S (1997). "Wasting as independent risk factor for mortality in chronic heart failure". The Lancet 349: 1050. doi:10.1016/S0140-6736(96)07015-8.
- ^ Hoogwerf (2000). "The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not". Cleveland Clinic journal of medicine 67 (4): 287–93. PMID 10780101.
- ^ a b Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3.[page needed]
- ^ Fein, A. 2009. ACE inhibitors worsen inflammatory pain. Medical Hypotheses 72: 757
- ^ Okumura, Hiromi; Nishimura, Eriko; Kariya, Satoru; Ohtani, Michiteru; Uchino, Katsuyoshi; Fukatsu, Tohru; Odanaka, Jun; Takahashi, Tsuyoshi et al. (March 2001). "Angiotensin-converting enzyme (ACE）阻害薬誘発性の咳嗽発現とACE 遺伝子型，血漿中ブラジキニン，サブスタンスP 及びACE 阻害薬濃度との関連性 [No Relation between Angiotensin-Converting Enzyme (ACE) Inhibitor-Induced Cough and ACE Gene Polymorphism, Plasma Bradykinin, Substance P and ACE Inhibitor Concentration in Japanese Patients]" (in Japanese). Yakugaku Zasshi 121 (3): 253–7. doi:10.1248/yakushi.121.253. PMID 11265121. http://www.jstage.jst.go.jp/article/yakushi/121/3/253/_pdf.
- ^ Thomas (2000). "Diuretics, ACE inhibitors and NSAIDs--the triple whammy.". The Medical journal of Australia 172 (4): 184–5. PMID 10772593.
- ^ Molinaro (2002). "Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin.". The Journal of pharmacology and experimental therapeutics 303 (1): 232–7. doi:10.1124/jpet.102.038067. PMID 12235256.
- ^ Sørensen AM, Christensen S, Jonassen TE, Andersen D, Petersen JS (March 1998). "[Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists]" (in Danish). Ugeskrift for Laeger 160 (10): 1460–4. PMID 9520613.
- ^ Fitzgerald (2004). "Hypotensive peptides from milk proteins.". The Journal of nutrition 134 (4): 980S–8S. PMID 15051858.
- ^ Aihara (2005). "Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension.". Journal of the American College of Nutrition 24 (4): 257–65. PMID 16093403.
- ^ a b Boelsma (2009). "Lactotripeptides and antihypertensive effects: a critical review.". The British journal of nutrition 101 (6): 776–86. doi:10.1017/S0007114508137722. PMID 19061526.
- ^ What are the dose comparisons of all ACE inhibitors used in hypertension? TripAnswers TRIP Database, May 25, 2007. Accessed 2009-11-21
- ^ Common Medication Conversions (Equivalents): Ace Inhibitors. GlobalRPh.com. Accessed 2009-11-22.
- ^ Treating High Blood Pressure and Heart Disease: the ACE Inhibitors. Consumer Reports Health Best Buy Drugs. June 2009.
- ^ Cooper (2006). "Major congenital malformations after first-trimester exposure to ACE inhibitors.". The New England journal of medicine 354 (23): 2443–51. doi:10.1056/NEJMoa055202. PMID 16760444.
- ^ a b Luno (2005). "The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).". Current pharmaceutical design 11 (10): 1291–300. doi:10.2174/1381612053507413. PMID 15853685.
- ^ Van De Wal (2005). "Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?". European heart journal 26 (22): 2361–7. doi:10.1093/eurheartj/ehi454. PMID 16105846.
- ^ Finnegan (2003). "Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.". The Annals of pharmacotherapy 37 (6): 886–9. doi:10.1345/aph.1C393. PMID 12773079.
- ^ Krum (2004). "Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.". European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 6 (7): 937–45. doi:10.1016/j.ejheart.2004.09.005. PMID 15556056.
- ^ Solomon (2005). "Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.". Circulation 111 (25): 3411–9. doi:10.1161/CIRCULATIONAHA.104.508093. PMID 15967846.
- ^ Yang (2005). "Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.". Clinical nephrology 64 (1): 35–40. PMID 16047643.
- ^ Ng, K. K. F. (1967). "Conversion of Angiotensin I to Angiotensin II". Nature 216 (5117): 762. doi:10.1038/216762a0. PMID 4294626.
- ^ Ng, K. K. F. (1968). "Fate of Angiotensin I in the Circulation". Nature 218 (5137): 144. doi:10.1038/218144a0. PMID 4296306.
- ^ Ng, K. K. F. (1970). "Some Properties of Angiotensin Converting Enzyme in the Lung in vivo". Nature 225: 1142. doi:10.1038/2251142b0.
- ^ Hata (1996). "A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects.". The American journal of clinical nutrition 64 (5): 767–71. PMID 8901799.
- ^ a b Nakamura (1995). "Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme.". Journal of dairy science 78 (6): 1253–7. PMID 7673515.